ADARx Pharmaceuticals, Inc. (ADRX) Stock Price & Analysis
ADARx Pharmaceuticals, Inc. (ADRX) closed at USD 17.7 on Thursday, October 15, 2026, down 0.73% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 17.83; the Oct 15, 2026 session ranged USD 17.5–18.32 on volume of 283,365 shares. Market capitalization is $1.89B, with a 52-week range of USD 16.64–23.21 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:05 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ADRX.md
Key facts (ADRX)
- Analysts: None.
- Total return with dividends: 1Y -8.5% vs S&P 500 +18.1%; 5Y -8.5% vs S&P 500 +85.1%.
Analysts (ADRX)
Consensus None.
Total return (dividends reinvested) (ADRX)
| 1Y (from 2026-09-25) | 5Y (from 2026-09-21) | |
|---|---|---|
| Total return | -8.5% | -8.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 55.8% | 19.3% |
| Max drawdown | -16.0% (Sep 2026→Oct 2026) | -8.5% (Sep 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:05 UTC)
| Price | USD 17.7 |
|---|---|
| Change | ▼ 0.73% (down) |
| Previous Close | USD 17.83 |
| Open | USD 17.75 |
| Day Range | USD 17.5 – 18.32 |
| 52-Week Range | USD 16.64 – 23.21 |
| Volume | 283,365 shares |
| Market Cap | $1.89B |
| Exchange | NMS |
Analyst Ratings (ADRX)
Wall Street analysts rate ADRX "None", per Nexqual as of October 16, 2026 at 05:05 UTC.
| Consensus Rating | None |
|---|
Earnings (ADRX)
Source: Nexqual, October 16, 2026 at 05:05 UTC.
Financials & Fundamentals (ADRX)
| Total Revenue | $6.13M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +258.70% |
| Gross Margin | +0.00% |
| Operating Margin | -4006.84% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.06 |
| Current Ratio | 12.98 |
| Total Cash | $427.25M |
| Total Debt | $6.90M |
Source: Nexqual, October 16, 2026 at 05:05 UTC.
Financial Health Score (ADRX)
Nexqual rates ADARx Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:05 UTC.
| Growth | Strong — Revenue +259% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $427M cash vs $7M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$88M (TTM) |
| Efficiency | Mixed — No data |
Ownership (ADRX)
| Insider Ownership | +41.78% |
|---|---|
| Institutional Ownership | +29.57% |
| Shares Outstanding | 106.80M |
| Float | 43.85M |
Source: Nexqual, October 16, 2026 at 05:05 UTC.
Leadership (ADRX)
ADARx Pharmaceuticals, Inc. is led by Zhen Li (age 63), Co-Founder, President, CEO & Director, per Nexqual as of October 16, 2026 at 05:05 UTC.
| Co-Founder, President, CEO & Director | Zhen Li (age 63) |
|---|---|
| Chief Scientific Officer | A. Robert MacLeod (age 58) |
| CFO & Chief Business Officer | Ryan Fisk (age 43) |
| Senior Vice President of Operations | Christopher Claeboe |
| Chief Technology Officer | Rui Zhu (age 42) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:05 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt